(News Bulletin 247) – The SpineGuard share stumbles on the Paris Stock Exchange this Friday despite the medical device manufacturer announcing strong growth in 2022 annual results and a cash position deemed ‘comfortable’.

The group, the origin of a surgical guidance technology to simplify the placement of bone implants, generated last year a turnover up 27% to 5.6 million euros.

Its EBITDA showed an improvement of 17% in 2022, with a loss of -888,000 euros against -1.06 million in 2021.

Its consolidated turnover for the first quarter amounted to 1.27 million euros against 1.13 million euros a year earlier, representing growth of 12% at actual rate (+10% at actual rate). constant).

After starting 2023 with double-digit growth, SpineGuard says it sees ‘great prospects’ for the rest of the year and reports a cash horizon longer than 24 months, offering ‘comfortable’ financial visibility according to analysts of Invest Securities.

Following these declarations, the title fell by more than 7% on Friday on the Paris Stock Exchange, suffering profit taking after having gained nearly 35% since the beginning of the year at the close of yesterday evening.

Copyright (c) 2023 News Bulletin 247. All rights reserved.